Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity

Lane, Steven, Gill, Devinder, McMillan, Nigel A. J., Saunders, Nicholas, Murphy, Rachel, Spurr, Terrence, Keane, Colm, Fan, Helen Mar and Mollee, Peter (2012) Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leukemia & Lymphoma, 53 6: 1077-1083.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Lane, Steven
Gill, Devinder
McMillan, Nigel A. J.
Saunders, Nicholas
Murphy, Rachel
Spurr, Terrence
Keane, Colm
Fan, Helen Mar
Mollee, Peter
Title Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity
Journal name Leukemia & Lymphoma   Check publisher's open access policy
ISSN 1042-8194
1029-2403
Publication date 2012-06
Sub-type Article (original research)
DOI 10.3109/10428194.2011.642302
Volume 53
Issue 6
Start page 1077
End page 1083
Total pages 7
Place of publication London, United Kingdom
Publisher Informa Healthcare
Collection year 2013
Language eng
Abstract Elderly patients with acute myeloid leukemia (AML) have a poor prognosis. The authors examined the in vitro and clinical activity of the histone deacetylase inhibitor valproic acid (VA) combined with cytosine arabinoside (AraC) in elderly patients with AML unsuited to intensive therapy. For the in vitro studies, primary AML cells from 11 patients were treated with AraC and VA and analyzed for apoptosis, cytostatic effects, differentiation and acetyl histone H3 induction. VA (alone and with AraC) enhanced apoptosis and induced acetyl histone H3. VA inhibited cell proliferation. For the clinical trial, 15 patients were treated with VA and subcutaneous AraC and assessed for toxicity and response. No complete or partial remissions were achieved. In concusion, VA has in vitro activity against AML and has additional activity with AraC. However, in this study, this combination demonstrated limited clinical activity in elderly patients with AML.
Keyword Acute myeloid leukemia
Elderley
Histone deacetylase inhibitor
Valproic acid
Cytosine arabinoside
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
School of Medicine Publications
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Access Statistics: 50 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 02 Jul 2012, 08:22:40 EST by System User on behalf of UQ Diamantina Institute